The following article features coverage from the Society of Gynecologic Oncology’s 50th Annual Meeting on Women’s Cancer. Click here to read more of Cancer Therapy Advisor‘s conference coverage.

In a small sample of women with ovarian cancer for whom simultaneous next-generation DNA sequencing was performed on paired germline and tumor specimens, test results influenced clinical decision-making for nearly 25% of patients. This study was presented at the Society of Gynecologic Oncology (SGO)’s 50th Annual Meeting on Women’s Cancer.

Targeted sequencing using the BROCA test, a gene panel designed for patients with a suspected hereditary cancer predisposition, was performed between July 2017 and July 2018 on paired peripheral blood (germline) and ovarian cancer tumor specimens (somatic) for 36 women with newly diagnosed ovarian cancer and 7 women with recurrent disease. Tumor specimens were obtained from surgical specimens, biopsy, or cytology in 72.1%, 25.6%, and 2.3% of cases, respectively.

Related Articles

A retrospective review of the medical records of these patients showed that the majority of women were white and had high-grade serous ovarian cancer. In 41.9% of cases with negative or inconclusive germline testing results, information on actionable molecular alterations was provided with paired somatic testing. With a median follow-up of 8.5 months, BROAC testing was shown to have influenced clinical decision-making (ie, decisions related to cancer screening or whether or not to recommend poly ADP ribose polymerase [PARP] inhibitors) for 10 patients (23.3%).  These decisions were based on identification of 7 somatic mutations (3 BRCA1, 2 BRCA2, 1 RAD51B, 1 BRIP1) and 3 germline mutations (1 BRCA1, 1 BRCA2, 1 PMS2).

Read more of Cancer Therapy Advisor‘s coverage of SGO’s annual meeting by visiting the conference page.

Reference

  1. Jorge S, McFaddin AS, Doll KM, et al. Simultaneous clinical testing for germline and somatic mutations in ovarian carcinoma (OC): Mutation rate and impact on therapeutic decisions Presented at: Society of Gynecologic Oncology (SGO)’s 50th Annual Meeting on Women’s Cancer; Honolulu, Hawaii; March 16-19, 2019. Abstract 6.